Over half of patients saw an improvement after being treated with biological therapies for inflammatory bowel disease (IBD), according to data from the first national report of biological therapies.
The report shows that 62% of adult patients and 73% of paediatric patients saw the severity of their disease decrease after 12 weeks of treatment with biological therapy. ‘Biological therapies’ is the collective term for two particular drugs – Infliximab (IFX) and Adalimumab (ADA). NICE recommends that these drugs are used for treatment of patients who have not responded to conventional therapy.
